- EISAI COMPLETES ACQUISITION OF MGI PHARMA
Tokyo, Japan, January 28, 2008 (U S Time) - Eisai Co , Ltd (Tokyo, TSE 4523) (“Eisai”), a research-based human health care (hhc) company, today announced the successful completion of its acquisition of MGI PHARMA, INC
- MGI Pharma Inc - Company Profile and News - Bloomberg Markets
MGI Pharma, Inc is an oncology-focused biopharmaceutical company that acquires, develops, and markets specialty pharmaceutical and medical products for therapeutic markets of unmet needs The
- MGI Pharma - Crunchbase Company Profile Funding
MGI PHARMA, INC , a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies
- MGI Pharma - Products, Competitors, Financials, Employees, Headquarters . . .
MGI Pharma is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients Use the CB Insights Platform to explore MGI Pharma's full profile
- MGI Pharma Inc | Reuters
The latest international MGI Pharma Inc news and views from Reuters - one of the world's largest news agencies
- Eisai Company, Ltd. Completes Acquisition of MGI PHARMA, INC.
TOKYO--(BUSINESS WIRE)--Eisai Co , Ltd (Tokyo, TSE 4523) (“Eisai”), a research-based human health care (hhc) company, today announced the successful completion of its acquisition of MGI PHARMA, INC
- Mgi Pharma , Inc. Information - RocketReach
MGI PHARMA, INC is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the unmet needs of patients
- MGI Pharma 2025 Company Profile: Valuation, Investors . . . - PitchBook
Information on acquisition, funding, investors, and executives for MGI Pharma Use the PitchBook Platform to explore the full profile
|